Guido Tricot

Active 1981–2025

131
Papers
27,400
Citations
93
h-index
128
i10-index

Citations

Citations per year for Guido Tricot1948: 7 citations1984: 4 citations1985: 10 citations1986: 16 citations1987: 16 citations1988: 14 citations1989: 15 citations1990: 28 citations1991: 20 citations1992: 20 citations1993: 25 citations1994: 17 citations1995: 24 citations1996: 44 citations1997: 68 citations1998: 74 citations1999: 72 citations2000: 106 citations2001: 111 citations2002: 179 citations2003: 283 citations2004: 233 citations2005: 210 citations2006: 241 citations2007: 288 citations2008: 276 citations2009: 344 citations2010: 261 citations2011: 308 citations2012: 207 citations2013: 184 citations2014: 163 citations2015: 156 citations2016: 163 citations2017: 132 citations2018: 104 citations2019: 419 citations2020: 378 citations2021: 425 citations2022: 258 citations2023: 157 citations2024: 319 citations2025: 116 citations2026: 4 citations1949–1983: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,287 citing papers, 30.4% of this breakdownChina: 490 citing papers, 6.5% of this breakdownGermany: 475 citing papers, 6.3% of this breakdownItaly: 470 citing papers, 6.2% of this breakdownUnited Kingdom: 429 citing papers, 5.7% of this breakdownFrance: 424 citing papers, 5.6% of this breakdownSpain: 335 citing papers, 4.5% of this breakdownCanada: 256 citing papers, 3.4% of this breakdownNetherlands: 248 citing papers, 3.3% of this breakdownGreece: 173 citing papers, 2.3% of this breakdownAustralia: 156 citing papers, 2.1% of this breakdownBelgium: 145 citing papers, 1.9% of this breakdown
0%30.4%Other 21.8%

Fields

  • Medicine73.3%
  • Biochemistry, Genetics and Molecular Biology18.2%
  • Immunology and Microbiology5.7%
  • Social Sciences0.8%
  • Computer Science0.5%
  • Chemistry0.4%
  • Other1.1%

Topics

  • Multiple Myeloma Research and Treatments17.8%
  • Protein Degradation and Inhibitors6.5%
  • Peptidase Inhibition and Analysis3.6%
  • Hematopoietic Stem Cell Transplantation3.1%
  • Acute Myeloid Leukemia Research2.9%
  • Cancer Treatment and Pharmacology2.8%
  • Other63.3%

Coauthors

All papers

Open in search
  1. International uniform response criteria for multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the International Myeloma Working Group - Leukemia 2006 cited by 2,639

  2. The molecular classification of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2006 cited by 1,142

  3. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase

    Authors: , , , , , - Journal of Hematology & Oncology 2017 cited by 148

  4. NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

    Authors: , , , , , , , , , , , , , , , - Cancer Cell 2013 cited by 300

  5. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2006 cited by 916

  6. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

    Authors: , , , , , , , , , , , , , , , - Blood 2006 cited by 479

  7. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma

    Authors: , , , , , , , , - JAMA Network Open 2022 cited by 59

  8. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2024 cited by 43

  9. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

    Authors: , , , , , , , , , , , - Blood 2006 cited by 383

  10. Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 417

  11. Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2019 cited by 47

  12. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2021 cited by 42

  13. Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation

    Authors: , , , , , , , , , - Cancer Research 2015 cited by 109

  14. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma

    Authors: , , , , , , , , , , - Journal of Clinical Investigation 2018 cited by 92

  15. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2006 cited by 739

  16. Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma

    Authors: , , , - American Journal of Clinical Pathology 2004 cited by 389

  17. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myeloma

    Authors: , , , , , , , , , , - Blood 2007 cited by 172

  18. Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma

    Authors: , , , , , , , , , , , , , , - Cancer Research 2015 cited by 76

  19. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 41

  20. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages

    Authors: , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2024 cited by 31

  21. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2022 cited by 24

  22. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

    Authors: , , , , , , , , , , , , , , , , , , , - British Journal of Haematology 2007 cited by 326

  23. Infusion of haplo‐identical killer immunoglobulin‐like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

    Authors: , , , , , , , , , , , , , - British Journal of Haematology 2008 cited by 193

  24. Tumor lysate–specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy

    Authors: , , , , - Blood 2002 cited by 150